CPC A61K 48/0066 (2013.01) [A61P 35/00 (2018.01); C12N 15/113 (2013.01)] | 31 Claims |
1. A method of treating a solid-tumor cancer in a subject in need thereof, the method comprising:
administering to the subject a composition comprising an shRNA or siRNA specific for Myc target protein 1 (MYCT1) mRNA, wherein the shRNA or siRNA reduces MYCT1 protein expression in endothelial cells at a tumor of the solid-tumor cancer, which reduces tumor angiogenesis and increases cytotoxic T cell transendothelial migration at the tumor in the subject.
|